Press Release: 11/18/2026
New American Lung Association Report on Lung Cancer Reveals Massachusetts Among Best in Nation for Screening, Early Diagnosis, Survival and Treatment
The 9th annual ‘State of Lung Cancer’ report examines burden of lung cancer in Massachusetts
BOSTON, MA | November 16, 2026
Today, the American Lung Association in Massachusetts released its annual “State of Lung Cancer” report, which shows the toll lung cancer takes on each state in the country. Lung cancer remains the leading cause of cancer deaths in Massachusetts and the U.S. Nationally, more than 229,000 people will be diagnosed with the disease this year. For Massachusetts, the report finds the state ranks first in the nation for five-year lung cancer survival at 40.9%, compared with 31% nationally. Massachusetts also ranks first in the nation for lung cancer screening and surgery as first course of treatment and second for both early-stage diagnosis and for having one of the lowest rates of people receiving no treatment.
“Overall, our report reveals positive news—more people in the U.S. are living longer after a lung cancer diagnosis than ever before, and more people are getting screened for the disease. While these findings give us hope, more must be done to end the burden of this devastating disease on families throughout Massachusetts,” said Lance Boucher, assistant vice president of state public policy for the American Lung Association. “We need to increase screening rates among those at high risk to catch the disease early when it’s more likely to be curable, expand comprehensive biomarker testing to help identify targeted treatments, and improve access to clinical trials and the best lung cancer care.”
The “State of Lung Cancer” report examines key lung cancer indicators and ranks Massachusetts:
- 35 out of 51 in the nation for rate of new lung cancer cases, at 57.7 per 100,000. The national rate is 52.1 per 100,000. This marks an 18% improvement over the past five years.
- 1 out of 43 in the nation for survival, at 40.9%. Most lung cancer cases are diagnosed at later stages when the cancer has spread, and treatment options are less likely to be curative. The national rate of people living five years after a lung cancer diagnosis is 31.0%.
- 2 out of 47 in the nation for early diagnosis, at 37.2%. The earlier lung cancer is diagnosed, the more likely that treatments will be effective. Nationally, only 29.3% of cases are diagnosed at an early stage. This represents a 10% improvement over the past five years.
- 1 out of 40 in the nation for surgical treatment, at 32.7%. Lung cancer can often be treated with surgery if it is diagnosed at an early stage and has not spread. Nationally, 21.4% of cases underwent surgery.
- 2 out of 47 in the nation for lack of treatment, at 13.6%. While there are multiple reasons why people may not receive treatment after a lung cancer diagnosis, no one should go untreated because of lack of provider or patient knowledge, lung cancer stigma, fatalism after diagnosis or cost of treatment. Nationally, 20.9% of cases receive no treatment.
- 1 out of 50 in the nation for lung cancer screening, at 38.7%. Lung cancer screening with annual low-dose CT scans for people at high risk can reduce the lung cancer death rate by up to 20%. Nationally, only 24.4% of people at high risk were screened.
- 6 out of 48 in the nation for smoking, at 8.2%. Tobacco use is the leading risk factor for lung cancer. Both smoking and secondhand smoke have been shown to cause lung cancer.
- 25 out of 51 in the nation for radon, at 21.8%. Radon, a colorless and odorless gas that can be present at high levels inside homes and buildings, is the second leading cause of lung cancer. Every home should be regularly tested for radon and mitigated if results are high.
The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing, which can help identify more personalized treatment options for a person’s specific type of lung cancer, including targeted therapies and immunotherapy. Insurance coverage of comprehensive biomarker testing is critical for making this test more accessible, but 24 states and Washington, D.C., do not require any coverage. The report found that Massachusetts does not require insurance coverage of comprehensive biomarker testing.
Additionally, clinical trials are essential to improving outcomes for people affected by lung cancer and increasing survival rates. Unfortunately, too many people face barriers that prevent them from participating in and benefit from cutting edge research. The Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which includes critical steps to make clinical trials accessible to more people and advance research and care for all.
The Lung Association brings research, advocacy and health promotions together to address lung cancer, investing in science, advocating for better access to prevention and care, and providing education, support and resources to help individuals navigate timely access to screening, diagnosis and treatment.
Learn more about the “State of Lung Cancer” report and take action to help end lung cancer at Lung.org/solc.
Get involved and help the mission of the American Lung Association. The Fight For Air Climb Boston is coming up on April 3, 2027. Learn more at FightForAirClimb.org/boston.
###
About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org. To support the work of the American Lung Association, find a local event at Lung.org/events.